Corsair Capital Management L.P. Purchases New Holdings in enVVeno Medical Corporation (NASDAQ:NVNO)

Corsair Capital Management L.P. purchased a new stake in shares of enVVeno Medical Corporation (NASDAQ:NVNO) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 116,000 shares of the company’s stock, valued at approximately $390,000. Corsair Capital Management L.P. owned about 0.66% of enVVeno Medical at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of NVNO. Westside Investment Management Inc. grew its position in shares of enVVeno Medical by 933.7% in the second quarter. Westside Investment Management Inc. now owns 38,762 shares of the company’s stock valued at $204,000 after purchasing an additional 35,012 shares in the last quarter. Fermata Advisors LLC grew its position in shares of enVVeno Medical by 33.4% in the second quarter. Fermata Advisors LLC now owns 30,949 shares of the company’s stock valued at $162,000 after purchasing an additional 7,751 shares in the last quarter. Quadrature Capital Ltd bought a new stake in enVVeno Medical during the first quarter valued at $103,000. Acadian Asset Management LLC bought a new stake in enVVeno Medical during the first quarter valued at $37,000. Finally, Vanguard Group Inc. lifted its stake in enVVeno Medical by 70.6% during the first quarter. Vanguard Group Inc. now owns 573,955 shares of the company’s stock worth $3,122,000 after purchasing an additional 237,550 shares during the last quarter. 34.71% of the stock is owned by hedge funds and other institutional investors.

enVVeno Medical Price Performance

NASDAQ NVNO opened at $3.21 on Wednesday. enVVeno Medical Corporation has a 1-year low of $3.01 and a 1-year high of $6.97. The stock has a 50-day moving average of $3.57 and a 200-day moving average of $4.62.

enVVeno Medical (NASDAQ:NVNO) last released its earnings results on Thursday, October 31st. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.02). As a group, equities research analysts forecast that enVVeno Medical Corporation will post -1.3 earnings per share for the current year.

About enVVeno Medical

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).